[1]闫祯昕,尹 非,李雪晨,等.黄嘌呤氧化酶抑制剂筛选体系的建立[J].中国药理学通报,2019,(10):1471-1477.[doi:10.3969/j.issn.1001-1978.2019.10.025]
 YAN Zhen-xin,YIN Fei,LI Xue-chen,et al.Establishment of a screening system for xanthine oxidase(XOD)inhibitors[J].Chinese Pharmacological Bulletin,2019,(10):1471-1477.[doi:10.3969/j.issn.1001-1978.2019.10.025]





Establishment of a screening system for xanthine oxidase(XOD)inhibitors
闫祯昕尹 非李雪晨姜 楠田金英叶 菲
中国医学科学院北京协和医学院药物研究所,新药作用机制研究与药效评价北京市重点实验室,北京 100050
YAN Zhen-xin YIN Fei LI Xue-chen JIANG Nan TIAN Jin-ying YE Fei
Beijing Key Lab of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
黄嘌呤氧化酶 高尿酸血症 抑制剂 高通量筛选 急性高尿酸血症小鼠模型 慢性高尿酸血症小鼠模型
xanthine oxidase hyperuricemia inhibitor high throughput screening acute hyperuricemia mouse model chronic hyperuricemia mouse model
R-332; R322.47; R345.49; R363-332; R446.11; R589.9; R977.3
目的 建立黄嘌呤氧化酶(xanthine oxidase, XOD)抑制剂筛选体系。方法 应用理化法,测定体外XOD活性、血尿酸、血清XOD活性、组织XOD活性及肝肾功能有关血液指标; 病理分析肝脏肾脏的损伤情况。结果 选择牛奶来源XOD 3 U·L-1,黄嘌呤(Xanthine, XA)50 μmol·L-1,37 ℃,pH 7.4, 20 min为XOD抑制剂体外高通量筛选的最适条件。单次灌胃次黄嘌呤联合皮下注射氧嗪酸钾诱导ICR小鼠,血尿酸水平一过性升高; 以血尿酸变化曲线和血尿酸-时间曲线下面积评价急性高尿酸血症小鼠模型。ICR小鼠连续皮下注射氧嗪酸钾血尿酸平稳升高,成模率约70%; 以血尿酸水平评价慢性高尿酸血症小鼠模型。上述2种模型动物的血清和组织XOD活性均未见明显变化,肝脏肾脏均未见明显损伤。结论 XOD抑制剂体外筛选方法与急性高尿酸血症小鼠模型、慢性高尿酸血症小鼠模型等体内实验方法相互验证,形成基于分子靶点XOD的抗高尿酸血症药物研发的实验体系。
Aim To establish a screening system for xanthine oxidase(XOD)inhibitors.Methods The XOD activity in vitro, serum uric acid level, serum XOD activity, tissue XOD activity and the blood indexes related to liver and kidney function were determined by biochemical method, respectively.Pathological analysis was used to observe liver and kidney.ResultsThe optimized reaction consists of 3 U·L-1 XOD and 50 μmol·L-1 XA under pH7.4, 37 ℃ for 20 min.The high throughput screening method was established for XOD inhibitors in vitro.The acute hyperuricemia models were induced by signle dose of hypoxanthine and oteracil potassium in ICR mice.In this case, the serum uric acid level had a transient elevation after inducer administered.The changes of serum uric acid levels and the area under the uric acid-time curve were used to evaluate the acute hyperuricemia mice.The chronic hyperuricemia models were selected from the ICR mice stimulated with oteracil potassium consecutively.No significant changes of XOD activities in serum and tissue, of function and pathological structure in liver and kidney were observed in both acute hyperuricemia mice and chronic hyperuricemia mice.Conclusions The high throughput screening method for XOD inhibitors in vitro and the evaluation in vivo, in acute or chronic hyperuricemia mice, respectively, are mutually verified, forming an experimental system for developing the anti-hyperuricemia drug targeting at XOD.


[1] Dalbeth N, Merriman T R, Stamp L K.Gout[J].Lancet, 2016,388(10055):2039-52.
[2] 孙 琳, 王桂侠, 郭蔚莹.高尿酸血症研究进展[J].中国老年学杂志, 2017,37(4):1034-8.
[2] Sun L, Wang G X, Guo W Y.The progress of study on hyperuricemia[J].Chin J Gerontol, 2017,37(4):1034-8.
[3] Chen D, Zhang H, Gao Y, et al.Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome: results from fangchenggang area male health and examination survey in China[J].Clin Chim Acta, 2015,446:226-30.
[4] Liu Z, Que S, Zhou L, Zheng S.Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a Meta-analysis of prospective studies[J].Sci Rep, 2015,5:14325.
[5] 林志健, 李 凡, 张 冰.禽类动物高尿酸血症的研究进展[J].中国实验动物学报, 2017,25(5):572-6.
[5] Lin Z J, Li F, Zhang B.Advances in research on hyperuricemia in avians[J].Acta Laboratorium Animalis Scientia Sin, 2017,25(5):572-6.
[6] Kurosaki M, Li Calzi M, Scanziani E, et al.Tissue-and cell-specific expression of mouse xanthine oxidoreductase gene in vivo: regulation by bacterial lipopolysaccharide[J].Biochem J,1995,306(Pt 1):225-34.
[7] Grewal H K, Martinez J R, Espinoza L R.Febuxostat: drug review and update[J].Expert Opin Drug Metab Toxicol, 2014,10(5):747-58.
[8] Heimbach E J, Bowden R G, Griggs J O, et al.The effects of lowering uric acid levels using allopurinol on components of metabolic syndrome[J].Cardiol Res, 2012,3(2):80-6.
[9] Maiuolo J, Oppedisano F, Gratteri S, et al.Regulation of uric acid metabolism and excretion[J].Int J Cardiol, 2016,213:8-14.
[10] Ojha R, Singh J, Ojha A, et al.An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout(2011-2015)[J].Expert Opin Ther Pat, 2017,27(3):311-45.
[11] Li L Z, Zhou G X, Li J, et al.Compounds containing trace element copper or zinc exhibit as potent hyperuricemia inhibitors via xanthine oxidase inactivation[J].J Trace Elem Med Biol, 2018,49:72-8.
[12] Wan Y, Liang Y X, Zou B, et al.The possible mechanism of hydroxytyrosol on reducing uric acid levels[J].J Functional Foods, 2018,42:319-26.
[13] Ao G Z, Zhou M Z, Li Y Y, et al.Discovery of novel curcumin derivatives targeting xanthine oxidase and urate transporter 1 as anti-hyperuricemic agents[J].Bioorg Med Chem, 2017,25(1):166-74.
[14] Wu X W, Muzny D M, Lee C C, Caskey C T.Two independent mutational events in the loss of urate oxidase during hominoid evolution[J].J Mol Evol,1992,34(1):78-84.
[15] 陈 刚, 谭明亮.茶多酚对高尿酸血症小鼠尿酸产生与排泄的影响及机制研究[J].中国药理学通报, 2017,33(2):218-22.
[15] Chen G,Tan M L.Effect of green tea polyphenols on uric acid level in potassium oxonate-induced hyperuricemic mice and mechanism[J].Chin Pharmacol Bull, 2017,33(2):218-22.


 WU Xin rong,ZANG Lu ping,LIU Zhi gang.Research advances on drug therapy targets in hyperuricemia[J].Chinese Pharmacological Bulletin,2010,(10):1410.
 HUANG Jing-qun,ZHUMiao-zhang,WANG Si-wang.Effects ofG enistein,Apigenin,Quercetin,Rutin and Astilbin on xanthine oxidase activities and serum uric acid levels in hyperuricem ic m ice [J].Chinese Pharmacological Bulletin,2011,(10):561.
[3]徐慧静,张 灏,刘春花,等. 摄食海参皂苷对小鼠高尿酸血症的影响[J].中国药理学通报,2011,(08):1064.
 XU Hui-jing,ZHANG Hao,LIU Chun-hua,et al. The effect of dietary sea cucumber saponin on hyperuricem ia in m ice[J].Chinese Pharmacological Bulletin,2011,(10):1064.
[4]陈 刚,谭明亮.茶多酚对高尿酸血症小鼠尿酸产生与排泄的影响及机制研究[J].中国药理学通报,2017,(02):218.[doi:10.3969/j.issn.1001-1978.2017.02.015]
 CHEN Gang,TAN Ming-liang.Effect of green tea polyphenols on uric acid level in potassium oxonate-induced hyperuricemic mice and mechanism[J].Chinese Pharmacological Bulletin,2017,(10):218.[doi:10.3969/j.issn.1001-1978.2017.02.015]
[5]陈 刚,贾 萍.别嘌醇改善果糖诱导的大鼠高尿酸血症与调节肠道葡萄糖转运子表达的关系研究[J].中国药理学通报,2017,(04):469.[doi:10.3969/j.issn.1001-1978.2017.04.006]
 CHEN Gang,JIA Ping.Effect of allopurinol on serum level of uric acid and intestinal expression of glucose transporters in rats with fructose-induced hyperuricemia[J].Chinese Pharmacological Bulletin,2017,(10):469.[doi:10.3969/j.issn.1001-1978.2017.04.006]
 YANG Xu-juan,HUANG Xi,TIAN Zhou,et al.Establishment of a novel hyperuricemia animal model using mice and assessment of hyporuricemia action of PNP inhibitor Ulodesine[J].Chinese Pharmacological Bulletin,2017,(10):883.[doi:10.3969/j.issn.1001-1978.2017.06.027]
[7]杨 兰,周云莉,李 瑶,等.尿酸酶-过氧化氢酶脂质体的特性分析及药效学研究[J].中国药理学通报,2017,(09):1211.[doi:10.3969/j.issn.1001-1978.2017.09.007]
 YANG Lan,ZHOU Yun-li,LI Yao,et al.Property and pharmacodynamics of uricase-catalase liposomes[J].Chinese Pharmacological Bulletin,2017,(10):1211.[doi:10.3969/j.issn.1001-1978.2017.09.007]
[8]周 洁,孙 超,李 飞.中药活性成分降尿酸作用机制研究进展[J].中国药理学通报,2018,(01):19.[doi:10.3969/j.issn.1001-1978.2018.01.006]
 ZHOU Jie,SUN Chao,LI Fei.Research advances in mechanism of active components of traditional Chinese medicine for reducing uric acid[J].Chinese Pharmacological Bulletin,2018,(10):19.[doi:10.3969/j.issn.1001-1978.2018.01.006]
 YANG Hai-guang,ZHOU Qi-meng,WANG Hai-gang,et al.Effect of mangiferin(crystal Ⅴ)on hyperuricemia mice induced by potassium oxonate and its mechanism[J].Chinese Pharmacological Bulletin,2018,(10):1356.[doi:10.3969/j.issn.1001-1978.2018.10.007]


收稿日期:2019-07-11,修回日期:2019-08-15 基金项目:国家自然科学基金青年基金项目(No 81600546); 中国医学科学院医学与健康科技创新工程团队项目(No CIFMS-2016-I2M-3-012); 国家“重大新药创制”科技重大专项(No 2018ZX09711001-003-005) 作者简介:闫祯昕(1994-),女,硕士生,研究方向:抗代谢综合征药理学,E-mail: 510482806@qq.com; 叶 菲(1964-),女,研究员,硕士生导师,研究方向:抗代谢综合征药理学,通讯作者,E-mail: yefei@imm.ac.cn
更新日期/Last Update: 2019-09-15